These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2822723)

  • 1. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients.
    Munster AM; Moran KT; Thupari J; Allo M; Winchurch RA
    J Burn Care Rehabil; 1987; 8(5):376-80. PubMed ID: 2822723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention with pseudomonas immune globulin in burn injury patients with inhalation trauma: does it have an effect on lung function and outcome?].
    Stuttmann R; Hebebrand D; Hartert M; Spilker G; Doehn M
    Klin Wochenschr; 1991; 69 Suppl 26():168-77. PubMed ID: 1813715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial.
    Jones EB
    Burns; 1995 Jun; 21(4):267-72. PubMed ID: 7662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte phenotype and function changes in burn patients after intravenous IgG therapy.
    Burleson DG; Mason AD; McManus AT; Pruitt BA
    Arch Surg; 1988 Nov; 123(11):1379-82. PubMed ID: 3178486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis.
    Hansbrough JF; Miller LM; Field TO; Gadd MA
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S49-56. PubMed ID: 3041358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients.
    Waymack JP; Jenkins ME; Alexander JW; Warden GD; Miller AC; Carey M; Ogle CK; Kopcha RG
    Burns; 1989 Apr; 15(2):71-6. PubMed ID: 2500137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pseudomonas immunoglobulin prophylaxis in patients with burn injuries].
    Stuttmann R; Petrovici V; Hartert M
    Infection; 1987; 15 Suppl 2():S71-5. PubMed ID: 3112025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunoglobulin G therapy on serum antibody titers to cytomegalovirus in burn patients.
    Moran KT; Thupari JN; O'Reilly TJ; Munster AM
    Am J Surg; 1988 Feb; 155(2):294-7. PubMed ID: 2829640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention using a Pseudomonas immunoglobulin in burn patients].
    Stuttmann R; Petrovici V; Hartert M
    Infection; 1987; 15(1):80-4. PubMed ID: 3106234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum IgG concentrations and antibody titer of burn patients after preventive intravenous IgG substitution with a Pseudomonas immunoglobulin].
    Stuttmann R; Hartert M; Jahn M; Spilker G; Doehn M
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():48-55. PubMed ID: 8499751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic intubation and continuous positive airway pressure in the management of inhalation injury in burn victims.
    Venus B; Matsuda T; Copiozo JB; Mathru M
    Crit Care Med; 1981 Jul; 9(7):519-23. PubMed ID: 7016441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil intracellular kill following thermal injury. Different bactericidal capability for patients' organisms and laboratory organisms.
    Moran KT; Allo MM; O'Reilly TJ; Karadsheh DF; Munster AM
    Arch Surg; 1988 Jun; 123(6):686-8. PubMed ID: 3285805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Septicaemia after burn injury: a comparative study.
    Bang RL; Sharma PN; Sanyal SC; Al Najjadah I
    Burns; 2002 Dec; 28(8):746-51. PubMed ID: 12464472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of a new pH 4.25 intravenous immunoglobulin preparation (gamimune-N).
    Pirofsky B
    J Infect; 1987 Jul; 15 Suppl 1():29-37. PubMed ID: 3117898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial.
    Zhou YP; Jiang ZM; Sun YH; Wang XR; Ma EL; Wilmore D
    JPEN J Parenter Enteral Nutr; 2003; 27(4):241-5. PubMed ID: 12903886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of bacterial and viral infections to attributable mortality in patients with severe burns: an autopsy series.
    D'Avignon LC; Hogan BK; Murray CK; Loo FL; Hospenthal DR; Cancio LC; Kim SH; Renz EM; Barillo D; Holcomb JB; Wade CE; Wolf SE
    Burns; 2010 Sep; 36(6):773-9. PubMed ID: 20074860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant use of intravenous lidocaine for procedural burn pain relief: a randomized double-blind, placebo-controlled, cross-over trial.
    Wasiak J; Spinks A; Costello V; Ferraro F; Paul E; Konstantatos A; Cleland H
    Burns; 2011 Sep; 37(6):951-7. PubMed ID: 21497022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of endotoxemia in burn patients by use of polymyxin B.
    Munster AM; Xiao GX; Guo Y; Wong LA; Winchurch RA
    J Burn Care Rehabil; 1989; 10(4):327-30. PubMed ID: 2551907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparison of early fluid therapy in extensive flame burns between inhalation and noninhalation injuries.
    Dai NT; Chen TM; Cheng TY; Chen SL; Chen SG; Chou GH; Chou TD; Wang HJ
    Burns; 1998 Nov; 24(7):671-5. PubMed ID: 9882069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial.
    de La Cal MA; Cerdá E; García-Hierro P; van Saene HK; Gómez-Santos D; Negro E; Lorente JA
    Ann Surg; 2005 Mar; 241(3):424-30. PubMed ID: 15729064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.